News & Opinion
Top 10 Innovations
Cell & Molecular Biology
Disease & Medicine
Ecology & Environment
Genetics & Genomics
Pharma & Biotech
Image of the Day
Shoddy Preclinical Data Used in Clinical Trial Proposals
Kerry Grens | Apr 5, 2018
Applications for Phase 1 and 2 human studies in Germany frequently lack sufficient information about an intervention’s efficacy in animal experiments, according to a new study.
Want to Boost Reproducibility? Get Another Lab Involved
Jim Daley | Feb 22, 2018
Including as few as two labs in a study improved the odds of getting the true effect size by as much as 23 percentage points, according to a replication model.
Investigation Questions Transparency for Failed TB Vax
Jef Akst | Jan 11, 2018
inquiry finds that researchers presented only select results from animal experiments when applying for funding and approval for human trials.
DNA-Delivered Antibodies Fight Off Lethal Bacterial Infection
Catherine Offord | Oct 3, 2017
Mice receiving the treatment produced their own monoclonal antibodies and survived infection with the life-threatening pathogen
Parkinson’s Disease Cell Therapy Relieves Symptoms in Monkeys
Abby Olena | Aug 30, 2017
Neurons derived from human induced pluripotent stem cells fill in for lost dopamine neurons in a primate model of the disease.
Preclinical Cancer Studies Not as Reproducible as Thought
Jef Akst | Jun 30, 2017
Researchers overestimate the reliability of findings from animal studies that are part of the Reproducibility Project: Cancer Biology.
Preclinical Studies Don't Regularly Adhere to Best Practices
Kerry Grens | May 8, 2017
Animal experiments published in a handful of cardiovascular journals mostly ignore NIH guidelines.
New Gene Therapy Shrinks Aggressive Tumors in Mice
Aggie Mika | May 2, 2017
Scientists shut down cancer-causing fusion genes with CRISPR.
Evaluating Epigenome-Targeting Cancer Therapies
Jef Akst | Apr 3, 2017
At the annual American Association for Cancer Research meeting, researchers discuss the importance of understanding the epigenetic contributors to cancer progression and treatment response.
Rethinking a Cancer Drug Target
Catherine Offord | Mar 26, 2017
The results of a CRISPR-Cas9 study suggest that MELK—a protein thought to play a critical role in cancer—is not necessary for cancer cell survival.